FDA Approved Drugs by Medical Condition

Search by medical condition for drugs approved by the Food and Drug Administration (FDA) for sale in the United States. Select the letter below that corresponds to the first letter of the medical condition you are searching for and all approved drugs classified under that category will be listed below.

Idiopathic Pulmonary Fibrosis

Esbriet (pirfenidone) (by InterMune), Approved October 2014
For the treatment of idiopathic pulmonary fibrosis

Ofev (nintedanib) (by Boehringer Ingelheim), Approved October 2014
For the treatment of idiopathic pulmonary fibrosis

Impotence

Caverject (alprostadil) (by Upjohn), Approved on July 6, 1995
Treatment for impotence

Muse (by Vivus), Approved October 1996
Treatment for impotence

Viagra (by Pfizer), Approved March 1998
Treatment for impotence

Infertility

Bravelle (urofollitropin for injection, purified) (by Ferring Pharmaceuticals), Approved May 2002
Human-derived follicle-stimulating hormone (hFSH) for use in ovulation induction for the treatment of infertility.

Fertinex (urofollitropin for injection, purified) (by Serono Laboratories), Approved September 1996
Treatment for patients undergoing infertility treatments

Follistim (TM) (follitropin beta for injection) (by Organon), Approved September 1997
Treatment for infertility

Gonal-F (follitropin alfa for injection) (by Serono Laboratories), Approved September 1997
Treatment for infertility

Ovidrel (gonadotropin, chorionic human recombinant) (by Serono Laboratories), Approved September 2000
For the induction of final follicular maturation and early luteinization in infertile women

REPRONEX(menotropins for injection, USP) (by Ferring Pharmaceuticals), Approved February 1997
Generic equivalent of Pergonal

Inflammation

Humira (adalimumab) (by Abbvie), Approved July 2016
For the treatment of uveitis

Inflammatory Bowel Disease

Linzess (linaclotide) (by Forest Labs and Ironwood Pharmaceuticals), Approved August 2012
For the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation

Influenza

Fluad (trivalent influenza vaccine) (by Seqirus), Approved November 2015
For the prevention of influenza A and B

Flublok (seasonal influenza vaccine) (by Protein Sciences), Approved January 2013
For the active immunization against influenza virus subtypes A and type B

Flucelvax, Influenza Virus Vaccine (by Novartis), Approved November 2012
For the treatment of influenza virus subtypes A and type B

FluMist ( Influenza Virus Vaccine) (by MedImmune), Approved June 2003
For the prevention of disease caused by influenza A and B viruses

Hiberix (Haemophilus b Conjugate Vaccine; Tetanus Toxoid Conjugate) (by GlaxoSmithKline), August of 2009
For the prevention of invasive disease caused by Haemophilus influenzae type b.

Rapivab (peramivir injection) (by Biocryst), Approved December 2014
For the treatment of acute uncomplicated influenza in adults

Tamiflu capsule (by Roche), October 27, 1999
Oseltamivir phosphate capsule

Insomnia

Belsomra (suvorexant) (by Merck), Approved August 2014
For the treatment of insomnia

Intermezzo (zolpidem tartrate sublingual tablet) (by Transcept Pharmaceuticals), Approved November 2011
For the treatment of insomnia

Silenor (doxepin) (by Somaxon Pharma), Approved March 2010
For the treatment of insomnia

Interstitial Cystitis

Elmiron (pentosan polysulfate sodium) (by IVAX), Approved October 1996
Treatment for interstitial cystitis

Intra-Abdominal Infections

Zerbaxa (ceftolozane + tazobactam) (by Cubist Pharmaceuticals), Approved December 2014
For the treatment of complicated intra-abdominal and urinary tract infections

Iron Overload (Hemachromatosis)

Ferriprox (deferiprone) (by Apotex), Approved October 2011
For the treatment of transfusional iron overload due to thalassemia

Irritable Bowel Syndrome (IBS)

Linzess (linaclotide) (by Forest Labs and Ironwood Pharmaceuticals), Approved August 2012
For the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation

Lotronex (alosetron HCL) Tablets (by GlaxoSmithKline), Approved February 2000
Indicated for Irritable Bowel Syndrome (IBS) in females with diarrhea-predominant IBS

Viberzi (eluxadoline) (by Actavis), Approved May 2015
For the treatment of irritable bowel syndrome with diarrhea

Xifaxan (rifaximin) (by Salix Pharmaceuticals), Approved May 2015
For the treatment of irritable bowel syndrome with diarrhea

Zelnorm (tegaserod maleate) Tablets (by Novartis), Approved July 2002
For the short-term treatment of irritable bowel syndrome in women whose primary bowel symptom is constipation